8-K: Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Dexcom's revenue grew 8% year-over-year in Q4 2024 to $1.114 billion, with full-year revenue reaching $4.033 billion, an 11% increase.

Summary

• Dexcom reported its financial results for the fourth quarter and fiscal year ended December 31, 2024.
• Revenue for Q4 2024 grew 8% year-over-year to $1.114 billion on a reported basis.
• U.S. revenue grew 4% and international revenue grew 17% in Q4 2024.
• GAAP operating income for Q4 2024 was $188.9 million, or 17.0% of revenue.
• Full-year revenue grew 11% versus the prior year to $4.033 billion on a reported basis.
• U.S. revenue growth for the full year was 10%, and international revenue growth was 15%.
• GAAP operating income for the full year was $600.0 million, or 14.9% of revenue.
• Dexcom submitted its Dexcom G7 15-day CGM system to the FDA for review.
• The company secured reimbursement for Dexcom ONE+ in France for people with type 2 diabetes on basal insulin.
• Dexcom announced a strategic partnership with URA, enabling integration of Dexcom glucose data with vital sign, sleep, stress, heart health, and activity data from Oura Ring.
• Dexcom launched its first generative AI feature in glucose biosensing, providing Stelo customers with personalized content.
• Dexcom is reiterating its fiscal year 2025 guidance for revenue of $4.60 billion (14% growth).
• Non-GAAP Gross Profit Margin is expected to be approximately 64% 65%.
• Non-GAAP Operating Margin is expected to be approximately 21%.
• Adjusted EBITDA Margin is expected to be approximately 30%.

Sentiment

Score: 6

Explanation: While revenue growth is positive, the decrease in operating income and net income tempers the overall sentiment. The guidance for 2025 is encouraging, but the current results show some margin pressure.

Positives

• Dexcom achieved solid revenue growth in both Q4 and full-year 2024.
• International revenue growth significantly outpaced U.S. revenue growth.
• The submission of Dexcom G7 15-day CGM system to the FDA is a positive step for future product offerings.
• Securing reimbursement for Dexcom ONE+ in France expands market access.
• The partnership with URA and the launch of the AI feature in Stelo demonstrate innovation.
• The company is reiterating strong revenue guidance for 2025.

Negatives

• GAAP operating income decreased in both Q4 and full-year 2024 compared to the prior year.
• Non-GAAP operating income also decreased in both Q4 and full-year 2024 compared to the prior year.
• GAAP net income decreased in Q4 2024 compared to Q4 2023.
• Gross profit margin decreased in Q4 2024 compared to Q4 2023.

Risks

• The company's future performance is subject to various risks and uncertainties described in Dexcom's SEC filings.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Dexcom is reiterating its fiscal year 2025 revenue guidance of $4.60 billion, representing 14% growth. Non-GAAP Gross Profit Margin is expected to be approximately 64% 65%, Non-GAAP Operating Margin is expected to be approximately 21%, and Adjusted EBITDA Margin is expected to be approximately 30%.

Management Comments

• In 2024, we implemented our largest US commercial sales force expansion, had two major product launches with Dexcom One+ and Stelo and submitted our G7 15-day product to the FDA, said Kevin Sayer, Dexcoms chairman, president and CEO.
• As we enter 2025, we look forward to building on these investments as we unlock the next wave of access to Dexcom CGM globally.

Industry Context

Dexcom's results reflect the ongoing demand for continuous glucose monitoring (CGM) technology in diabetes management. The company's focus on innovation, market expansion, and strategic partnerships positions it to compete effectively in the growing CGM market.

Comparison to Industry Standards

• Dexcom's revenue growth of 11% for the full year 2024 is solid, but it's important to compare this to competitors like Abbott (FreeStyle Libre) and Medtronic in the diabetes care space.
• Abbott's diabetes care segment has also shown strong growth, driven by FreeStyle Libre, and a detailed comparison of growth rates and market share would be insightful.
• Medtronic, while a larger player with a broader portfolio, is also a key competitor in the CGM market, and their performance provides a broader industry context.
• Dexcom's gross profit margin of around 60% is fairly standard for medical device companies, but analyzing trends and comparing it to Abbott and Medtronic's diabetes segments would be valuable.
• The adjusted EBITDA margin guidance of 30% for 2025 is a key profitability metric, and benchmarking this against peers is essential for assessing Dexcom's efficiency and profitability.

Stakeholder Impact

• Shareholders will be interested in the revenue growth and future guidance, but concerned about the decrease in operating income.
• Employees may be affected by the company's expansion and product launches.
• Customers will benefit from increased access to Dexcom's CGM technology and new product features.
• Suppliers will see increased demand for Dexcom's products.
• Creditors will be interested in Dexcom's strong cash position.

Next Steps

• Dexcom will continue to focus on expanding access to its CGM technology globally.
• The company will build on its investments in product development and commercial expansion.
• Dexcom will monitor the FDA review of its Dexcom G7 15-day CGM system.
• Dexcom will continue to integrate glucose data with other health metrics through partnerships.

Key Dates